New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
21:52 EDTMBLTYMesoblast announces trial results for precursor cells in heart failure
Mesoblast announced that trial results evaluating a low dose of Mesoblast's mesenchymal precursor cells in patients with end-stage or class IV New York Heart Association heart failure who receive a left ventricular assist device have been published in the June issue of the American Heart Association journal Circulation. At the trial's 90-day primary endpoint for safety and exploratory efficacy, a single low-dose injection of MPCs into the damaged heart muscle resulted in: decreased rate of immunization and allosensitization; increased proportion of patients successfully weaned from their LVAD mechanical support; decreased mortality rate.
News For MBLTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
09:50 EDTMBLTYMesoblast management to meet with JPMorgan
Meetings to be held in Boston on November 19 and in San Francisco on November 20-21 hosted by JPMorgan.
November 12, 2014
08:02 EDTMBLTYCredit Suisse to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use